These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16433181)

  • 21. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic-induced parkinsonism: impaired potentiation of the H-reflexes.
    Bartels M; Maltzahn DV; Mezger G
    Electromyogr Clin Neurophysiol; 1982; 22(1-2):9-20. PubMed ID: 6121699
    [No Abstract]   [Full Text] [Related]  

  • 23. [Neuroleptic parkinsonism].
    Izakson KhA
    Med Sestra; 1986 Sep; 45(9):50-2. PubMed ID: 2880275
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical characteristics of drug induced parkinsonism in psychotic patients].
    Giroud-Benítez JL; López-Suárez RM; Méndez-Chávez A; Vistorte-Pupo A; González-Torres R; López-Jaén I; Pradere-Pensado JC; Enriquez Lescano Gort L; Paz-Sendin L
    Rev Neurol; 2001 Dec 1-15; 33(11):1095-7. PubMed ID: 11785039
    [No Abstract]   [Full Text] [Related]  

  • 25. [A double-blind study on the effect of dexetimide in the control of neuroleptic-induced extrapyramidal side-effects].
    Chen Y
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Aug; 24(4):197-9, 251. PubMed ID: 1683277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anticholinergics during neuroleptic treatment. Value and withdrawal].
    Betermiez P; Delahousse J; Pedinielli JL
    Encephale; 1986; 12(4):169-74. PubMed ID: 2878801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critique of DSM-IV: associated features of neuroleptic-induced parkinsonism.
    Segraves T; Abdel-Dayem M
    Am J Psychiatry; 1996 Jun; 153(6):844. PubMed ID: 8633713
    [No Abstract]   [Full Text] [Related]  

  • 28. [New forms of Parkinsonism in hospice care].
    Baquero M; Domínguez-Sanz FJ; Burguera JA; Cruz Campos GA; Muñoz R
    Rev Neurol; 1995; 23(123):964-8. PubMed ID: 8556606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of the Kampo kami-shoyo-san (TJ-24) for tremor of antipsychotic-induced parkinsonism.
    Ishikawa T; Funahashi T; Kudo J
    Psychiatry Clin Neurosci; 2000 Oct; 54(5):579-82. PubMed ID: 11043809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroleptic-induced catatonia: case report.
    Johnson GC; Manning DE
    J Clin Psychiatry; 1983 Aug; 44(8):310-2. PubMed ID: 6874654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Parkinsonism during lithium use].
    Walrave TR; Bulens C
    Tijdschr Psychiatr; 2009; 51(2):123-7. PubMed ID: 19194854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validity and reliability of the Simpson-Angus Scale (SAS) in drug induced parkinsonism in the elderly.
    Knol W; Keijsers CJ; Jansen PA; Belitser SV; Schobben AF; Egberts AC; van Marum RJ
    Int J Geriatr Psychiatry; 2009 Feb; 24(2):183-9. PubMed ID: 18615779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects.
    Taira M; Hashimoto T; Takamatsu T; Maeda K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1139-42. PubMed ID: 16765499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism.
    Di Fabio R; De Filippis S; Cafariello C; Penna L; Marianetti M; Serrao M; Pierelli F
    Clin Neuropharmacol; 2013; 36(5):162-5. PubMed ID: 24045607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility to neuroleptic-induced parkinsonism--age and increased substantia nigra echogenicity as putative risk factors.
    Jabs BE; Bartsch AJ; Pfuhlmann B
    Eur Psychiatry; 2003 Jun; 18(4):177-81. PubMed ID: 12814851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?
    Melamed E; Achiron A; Shapira A; Davidovicz S
    Clin Neuropharmacol; 1991 Jun; 14(3):273-8. PubMed ID: 1676933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis.
    Teive HA; Troiano AR; Germiniani FM; Werneck LC
    Parkinsonism Relat Disord; 2004 Jun; 10(4):243-5. PubMed ID: 15120099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study.
    Dorfman-Etrog P; Hermesh H; Prilipko L; Weizman A; Munitz H
    Eur Neuropsychopharmacol; 1999 Dec; 9(6):475-7. PubMed ID: 10625114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.